Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.40 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2169980 | 0.88 | MMP2 (0.45) | TSHRALOX15MMP2MMP13ATM | |
| SCHEMBL2923191 | 0.86 | TSHR (0.46) | TSHRALOX15MMP2MMP13ATM | |
| SCHEMBL12983226 | 0.86 | TSHR (0.46) | TSHRALOX15MMP2MMP13ATM | |
| SCHEMBL2919135 | 0.79 | TSHR (0.48) | TSHRALOX15ATMACHECYP11B2 | |
| SCHEMBL2916674 | 0.78 | TSHR (0.45) | TSHRALOX15ATMACHECYP11B2 | |
| SCHEMBL2919971 | 0.77 | TSHR (0.42) | TSHRALOX15ATMACHECYP11B2 | |
| SCHEMBL971790 | 0.74 | TSHR (0.65) | TSHRALOX15ATMTACR1HSD11B1 | |
| SCHEMBL2152449 | 0.73 | ACHE (0.46) | TSHRALOX15MMP2MMP13ATM | |
| SCHEMBL31382726 | 0.70 | TSHR (0.51) | TSHRALOX15ATMHSD11B1PKM | |
| SCHEMBL31382005 | 0.69 | GPR119 (0.53) | TSHRALOX15ATMTACR1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858629-B2 | Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2010-12-28 | — | — | US | disclosed |
| EP-2010178-B1 | SUBSTITUTED IMIDAZOLE 4-CARBOXAMIDES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2010-09-01 | — | — | EP | disclosed |
| US-20090239862-A1 | 3-{(3S)-4-{[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl}-3 -[(isopropylamino)carbonyl]-1-piperazinyl}-1-naphthoic acid, useful for the treatment, control, or prevention of obesity and diabetes | MERCK SHARP & DOHME CORP. | 2009-09-24 | — | — | US | disclosed |
| EP-2010178-A4 | SUBSTITUTED IMIDAZOLE 4-CARBOXAMIDES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS | MERCK & CO INC (US) | 2009-04-29 | — | — | EP | disclosed |
| EP-2010178-A2 | SUBSTITUTED IMIDAZOLE 4-CARBOXAMIDES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007120688-A2 | SUBSTITUTED IMIDAZOLE 4-CARBOXAMIDES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239862-A1 | 3-{(3S)-4-{[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl}-3 -[(isopropylamino)carbonyl]-1-piperazinyl}-1-naphthoic acid, useful for the treatment, control, or prevention of obesity and diabetes | CCKAR, CCKBR, GIPR | TSHR 161/4885ALOX15 2817/4885MMP2 2486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.